International Space Station Major Constituent Analyzer On-Orbit Performance

The Major Constituent Analyzer (MCA) is an integral part of the International Space Station (ISS) Environmental Control and Life Support System (ECLSS). The MCA is a mass spectrometer-based instrument designed to provide critical monitoring of six major atmospheric constituents; nitrogen, oxygen, hydrogen, carbon dioxide, methane, and water vapor. These gases are sampled continuously and automatically in all United States On-Orbit Segment (USOS) modules via the Sample Distribution System (SDS). The MCA is the primary tool for management of atmosphere constituents and is therefore critical for ensuring a habitable ISS environment during both nominal ISS operations and campout EVA preparation in the Airlock. The MCA has been in operation in the US Destiny Laboratory Module for over 10 years, and a second MCA has been delivered to the ISS for Node 3 operation. This paper discusses the performance of the MCA over the two past year, with particular attention to lessons learned regarding the operational life of critical components. Recent data have helped drive design upgrades for a new set of orbit-replaceable units (ORUs) currently in production. Several ORU upgrades are expected to increase expected lifetimes and reliability

International Space Station Major Constituent Analyzer On-Orbit Performance

The Major Constituent Analyzer is a mass spectrometer based system that measures the major atmospheric constituents on the International Space Station. A number of limited-life components require periodic change-out, including the ORU 02 analyzer and the ORU 08 Verification Gas Assembly. Improvements to ion pump operation and ion source tuning have improved lifetime performance of the current ORU 02 design. The most recent ORU 02 analyzer assemblies, as well as ORU 08, have operated nominally. For ORU 02, the ion source filaments and ion pump lifetime continue to be key determinants of MCA performance and logistical support. Monitoring several key parameters provides the capacity to monitor ORU health and properly anticipate end of life

Hardware Design Improvements to the Major Constituent Analyzer

The Major Constituent Analyzer (MCA) onboard the International Space Station (ISS) is designed to monitor the major constituents of the ISS's internal atmosphere. This mass spectrometer based system is an integral part of the Environmental Control and Life Support System (ECLSS) and is a primary tool for the management of ISS atmosphere composition. As a part of NASA Change Request CR10773A, several alterations to the hardware have been made to accommodate improved MCA logistics. First, the ORU 08 verification gas assembly has been modified to allow the verification gas cylinder to be installed on orbit. The verification gas is an essential MCA consumable that requires periodic replenishment. Designing the cylinder for subassembly transport reduces the size and weight of the maintained item for launch. The redesign of the ORU 08 assembly includes a redesigned housing, cylinder mounting apparatus, and pneumatic connection. The second hardware change is a redesigned wiring harness for the ORU 02 analyzer. The ORU 02 electrical connector interface was damaged in a previous on-orbit installation, and this necessitated the development of a temporary fix while a more permanent solution was developed. The new wiring harness design includes flexible cable as well as indexing fasteners and guide-pins, and provides better accessibility during the on-orbit maintenance operation. This presentation will describe the hardware improvements being implemented for MCA as well as the expected improvement to logistics and maintenance

Investigation of International Space Station Major Constituent Analyzer Anomalous ORU 02 Performance

The Major Constituent Analyzer (MCA) is a mass spectrometer-based instrument designed to provide critical monitoring of six major atmospheric constituents; nitrogen, oxygen, hydrogen, carbon dioxide, methane, and water vapor on-board the International Space Station. It is an integral part of the Environmental Control and Life Support System (ECLSS). The MCA system is comprised of seven orbit-replaceable units (ORUs) that provide flexibility in maintaining the MCA. Of these, ORU 02, the analyzer assembly requires replacement every 1 to 2 years due to the consumption of limited life components including the ion pump and ion source filaments. Typically, ORU 02s that reach end of life are swapped out of the MCA on orbit and replaced with the on-orbit spare. The replaced ORU 02 is then returned to the OEM for refurbishment and is then return to service. Recently, 2 refurbished ORU 02s, serial numbers F0001 and F0003, failed on orbit shortly after being installed into the MCA. Both ORU 02s have been returned to ground for TT&E, and a failure investigation is underway. The failure signatures have been reproduced on the ground and an initial investigation has determined that both ORU 02 failures involve either the ion source or the ion source control electronics. This paper discusses the results of the failure investigation, the steps required to refurbish the ORU 02s, and the risk mitigation steps that are being incorporated into the refurbishment process to preclude the reoccurrence of these failures in the futur

Investigation of International Space Station Major Constituent Analyzer Anomalous ORU 02 Performance

The Major Constituent Analyzer (MCA) is a mass spectrometer based system that measures the major atmospheric constituents on the International Space Station. In 2011, two MCA ORU 02 analyzer assemblies experienced premature on-orbit failures. These failures were determined to be the result of off-nominal ion source filament performance. Recent product improvements to ORU 02 designed to improve the lifetime of the ion pump also constrained the allowable tuning criteria for the ion source filaments. This presentation describes the filament failures as well as the corrective actions implemented to preclude such failures in the future

Scientists' warning on climate change and insects

Climate warming is considered to be among the most serious of anthropogenic stresses to the environment, because it not only has direct effects on biodiversity, but it also exacerbates the harmful effects of other human-mediated threats. The associated consequences are potentially severe, particularly in terms of threats to species preservation, as well as in the preservation of an array of ecosystem services provided by biodiversity. Among the most affected groups of animals are insects—central components of many ecosystems—for which climate change has pervasive effects from individuals to communities. In this contribution to the scientists' warning series, we summarize the effect of the gradual global surface temperature increase on insects, in terms of physiology, behavior, phenology, distribution, and species interactions, as well as the effect of increased frequency and duration of extreme events such as hot and cold spells, fires, droughts, and floods on these parameters. We warn that, if no action is taken to better understand and reduce the action of climate change on insects, we will drastically reduce our ability to build a sustainable future based on healthy, functional ecosystems. We discuss perspectives on relevant ways to conserve insects in the face of climate change, and we offer several key recommendations on management approaches that can be adopted, on policies that should be pursued, and on the involvement of the general public in the protection effort

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat